SCHEMBL334661

SCHEMBL334661

O=C(NCCCC[C@@H]1CO1)c1cccc(Br)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.58
TP53BP1 Q12888 1/20 0.56
HPGD P15428 1/20 0.56
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HDAC1 Q13547 1/20 0.49
POLB P06746 1/20 0.48
MAPT P10636 3/20 0.47
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334352 0.99 LMNA (0.63) LMNAL3MBTL1TP53BP1HPGDNPC1
SCHEMBL334813 0.96 L3MBTL1 (0.59) LMNAL3MBTL1TP53BP1HPGDNPC1
SCHEMBL334382 0.91 L3MBTL1 (0.62) LMNAL3MBTL1TP53BP1HPGDNPC1
SCHEMBL9491289 0.83 LMNA (0.83) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL335221 0.82 HPGD (0.74) LMNAL3MBTL1TP53BP1HPGDNPC1
SCHEMBL4909099 0.79 LMNA (0.72) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL31055438 0.78 L3MBTL1 (0.82) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL334943 0.76 NPC1 (0.45) HPGDNPC1ALDH1A1SIGMAR1GAA
SCHEMBL335818 0.76 MAPT (0.50) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5657260 0.76 LMNA (1.00) LMNAL3MBTL1TP53BP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 LMNA 1467/4885L3MBTL1 2853/4885TP53BP1 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.